Omalizumab Current Price Trends and Purchasing Channel Guide

Omalizumab is a targeted biological agent targeting IgE antibodies. It is commonly used to treat moderate to severe allergic asthma, chronic spontaneous urticaria and other diseases. Since the drug was approved for marketing in mainland China in 2018, it has been widely used clinically due to its good therapeutic effect and controllable side effects. Especially after being included in the medical insurance catalog, the financial burden on patients has been significantly reduced, and the number of users has gradually expanded.

Currently in China, the price of omalizumab varies slightly depending on procurement channels and hospital pricing, but the price of a common specification of 150mg injection is about RMB1,000 yuan. This price is significantly more affordable than in foreign markets - for example, in the United States, the price of a single dose of the drug may exceed 2000 US dollars. The coverage of China’s medical insurance makes the actual out-of-pocket expenses even lower, and even more than 70% of them can be reimbursed in some areas, effectively improving patients’ medication accessibility.

In mainland China, patients mainly obtain omalizumab prescriptions through tertiary hospitals, specialist outpatient clinics or special disease outpatient clinics. Doctors inject the drug once every 2 to 4 weeks based on the patient's weight and condition assessment. After obtaining a doctor's prescription, the medicine is usually used in the hospital pharmacy or uniformly delivered to the injection department by the hospital. Currently, the drug is not available for purchase in retail pharmacies, so it cannot be purchased freely on ordinary online platforms or pharmacies.

Overall, the price of omalizumab in China has shown a relatively stable and gradually decreasing trend. Especially with the continuous optimization of medical insurance policies, more patients can afford this highly effective targeted drug. With the gradual launch of biosimilar drugs in the future and changes in the competitive landscape, the price of the drug is expected to further drop, allowing its therapeutic advantages to benefit more people in need.

Reference materials:https://www.drugs.com/

xa0